Healthcare
vTv Therapeutics Inc.(VTVT)
Live Price
Offline$33.92
+5.21% today
1Y Change
+123.45%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- $90.00M
- Revenue Growth
- -100.0%
- EPS Growth
- 0.0%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
vTv Therapeutics Inc. (VTVT) is a Healthcare stock with a market cap of $90.00M and listed on NASDAQ. The stock last traded around $33.92 and up 123.5% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS 0.0%, free cash flow +0.2% with operating margin 0.0% and ROIC -39.4%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VTVT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at 0.0%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +7.2% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | -3.1% | -6.1% | โ |
2026 Mar 10, 2026 | +40.8% | +0.2% | +4.8% | +9.8% |
2025 Nov 6, 2025 | -11.3% | +2.2% | +22.8% | +7.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VTVT
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VTVT Max Drawdown
-32.06%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VTVT and SPY.
Company Overview
vTv Therapeutics Inc.
NASDAQ Capital Market
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
- Leadership
- Paul J. Sekhri
- IPO Date
- Jul 30, 2015
- Employees
- 23
- Street Address
- 3980 Premier Drive
- Mailing
- High Point, NC, 27265
- Region
- High Point, NC, US
- Reporting Currency
- USD
- Investor Line
- 336 841 0300
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.1
- Price/Sales
- โ
- Price/Book
- 4.2
Growth
- Revenue
- -100.0%
- EPS
- 0.0%
- Free Cash Flow
- +0.2%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -74.1%
- ROIC
- -39.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 13.54
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.